WuXi Biologics (Cayman) Inc.
WuXi Biologics (Cayman) Inc. Fundamental Analysis
WuXi Biologics (Cayman) Inc. (WXXWY) shows moderate financial fundamentals with a PE ratio of 25.11, profit margin of 22.53%, and ROE of 10.54%. The company generates $22.4B in annual revenue with moderate year-over-year growth of 9.63%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 65.9/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze WXXWY's fundamental strength across five key dimensions:
Efficiency Score
WeakWXXWY struggles to generate sufficient returns from assets.
Valuation Score
ModerateWXXWY shows balanced valuation metrics.
Growth Score
ModerateWXXWY shows steady but slowing expansion.
Financial Health Score
ExcellentWXXWY maintains a strong and stable balance sheet.
Profitability Score
ModerateWXXWY maintains healthy but balanced margins.
Key Financial Metrics
Is WXXWY Expensive or Cheap?
P/E Ratio
WXXWY trades at 25.11 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, WXXWY's PEG of 0.22 indicates potential undervaluation.
Price to Book
The market values WuXi Biologics (Cayman) Inc. at 2.58 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 16.46 times EBITDA. This signals the market has high growth expectations.
How Well Does WXXWY Make Money?
Net Profit Margin
For every $100 in sales, WuXi Biologics (Cayman) Inc. keeps $22.53 as profit after all expenses.
Operating Margin
Core operations generate 30.48 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.54 in profit for every $100 of shareholder equity.
ROA
WuXi Biologics (Cayman) Inc. generates $7.63 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
WuXi Biologics (Cayman) Inc. produces operating cash flow of $4.07B, showing steady but balanced cash generation.
Free Cash Flow
WuXi Biologics (Cayman) Inc. produces free cash flow of $1.92B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.93 in free cash annually.
FCF Yield
WXXWY converts 1.45% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
25.11
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.22
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.58
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.88
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.07
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.14
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How WXXWY Stacks Against Its Sector Peers
| Metric | WXXWY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 25.11 | 28.23 | Better (Cheaper) |
| ROE | 10.54% | 737.00% | Weak |
| Net Margin | 22.53% | -46175.00% (disorted) | Strong |
| Debt/Equity | 0.07 | 0.35 | Strong (Low Leverage) |
| Current Ratio | 3.14 | 4.10 | Strong Liquidity |
| ROA | 7.63% | -17785.00% (disorted) | Weak |
WXXWY outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews WuXi Biologics (Cayman) Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
359.04%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
224.15%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
322.87%
Industry Style: Defensive, Growth, Innovation
High Growth